Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Total Non-Current Liabilities (2019 - 2025)

ENDRA Life Sciences has reported Total Non-Current Liabilities over the past 3 years, most recently at $280829.0 for Q1 2021.

  • Quarterly Total Non-Current Liabilities fell 13.8% to $280829.0 in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $280829.0 through Mar 2021, down 13.8% year-over-year, with the annual reading at $608992.0 for FY2020, 77.65% up from the prior year.
  • Total Non-Current Liabilities was $280829.0 for Q1 2021 at ENDRA Life Sciences, down from $608992.0 in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $645450.0 in Q2 2020 and troughed at $280829.0 in Q1 2021.
  • The 3-year median for Total Non-Current Liabilities is $358915.0 (2019), against an average of $455767.9.
  • Year-over-year, Total Non-Current Liabilities soared 77.65% in 2020 and then dropped 13.8% in 2021.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $342812.0 in 2019, then soared by 77.65% to $608992.0 in 2020, then plummeted by 53.89% to $280829.0 in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Total Non-Current Liabilities are $280829.0 (Q1 2021), $608992.0 (Q4 2020), and $627573.0 (Q3 2020).